




RealRate

PHARMACEUTICAL 2012

Biomarin Pharmaceutical INC
Rank 81 of 196

B:OMARIN®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 53% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	469,802
Cost of Goods Sold	84,023
Intangible Assets	231,820
Liabilities, Current	94,125
Liabilities, Non-Current	88,179
Other Assets	333,088
Other Compr. Net Income	0
Other Expenses	21,882
Other Liabilities	348,329
Other Net Income	508
Other Revenues	441,358
Property and Equipment	268,971
Research and Development	214,374
Selling, General and Administrative Expense	175,423

Output Variable	Value in 1000 USD
Assets	1,303,681
Liabilities	530,633
Expenses	495,702
Revenues	441,358
Stockholders Equity	773,048
Net Income	-53,836
Comprehensive Net Income	-53,836
BaseVar	1,385,941
ECR before LimitedLiability	178%
Economic Capital Ratio	287%